NCT01326702 · REGISTRY CONDITION SEARCH

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2019-12-16

This phase I/II trial studies the side effects and the best dose of veliparib when given together with bendamustine hydrochloride and rituximab and to see how well they work in treating patients with lymphoma, multiple myeloma, or solid tumors that have come back or have not responded to treatment. Veliparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Giving veliparib together with bendamustine hydrochloride and rituximab may kill more cancer cells.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximum Tolerated Dose of Veliparib When Combined With Bendamustine Hydrochloride

→

outcome · POSTED

Response Rate

→

outcome · POSTED

Number of Participants With Adverse Events

→

outcome · POSTED

Complete Response (CR) to Study Treatment (Phase IIa)

→

outcome · POSTED

Duration of Remission (Phase IIa)

→

outcome · POSTED

Overall Survival (Phase IIa)

→

outcome · POSTED

Pharmacokinetic Parameters of Veliparib (Phase Ib)

→

outcome · POSTED

Progression-free Survival Using RECIST Version 1.1 (Phase IIa)

→

outcome · POSTED

Participants With Dose Limiting Toxicities

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Phase 1b: Patients must have a histologically confirmed solid malignancy, lymphoma or multiple myeloma for which standard curative or palliative measures do not exist, are no longer effective, or for which the patient is not eligible or refuses; phase 1b cohort expansion: patients must have a histologically confirmed cluster of differentiation (CD)-20 positive B-cell non-Hodgkin lymphoma for which standard curative or palliative measures do not exist, are no longer effective, or for which the patient is not eligible or refuses; phase 2a: patients must have histologically or cytologically confirmed marginal zone B-cell lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma or mantle cell lymphoma, and must have at least one measureable site of disease * For lymphoma and multiple myeloma patients: patients who have relapsed or are refractory to at least one prior chemotherapeutic regimen or biologic agent; patients must either be ineligible for or have refused curative options for treatment, including stem cell transplant, if applicable * For solid tumor patients: relapsed or refractory to at least one prior chemotherapeutic regimen or biologic agent; patients must either be ineligible for or have refused curative options for treatment * Patients must have had a rest period of at least 3 weeks since prior chemotherapy or radiation therapy, 6 weeks if the last regimen included carmustine (BCNU) or mitomycin C; there must be a rest period of at least 3 months if the last therapy was immunotherapy or radioimmunotherapy (unless the disease has progressed since treatment) * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Life expectancy of greater than 3 months * Absolute neutrophil count (ANC) \>= 1,000/mcL * Platelets \>= 100,000/mcL unsupported by transfusion within the prior 2 weeks * Hemoglobin \>= 8.0 g/dL unsupported by transfusion within the prior 2 weeks * Total bilirubin =\< 2 x upper normal institutional limits; in patients with Gilbert's disease or documented liver metastases, total bilirubin up to 3 x upper limits of normal (ULN) will be allowed * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional upper limit of normal * Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min for patients with creatinine levels above institutional normal * Patients with prior stem cell transplant will be eligible as long as they have not relapsed or progressed within 100 days post-transplant and they meet the above inclusion criteria * Women of child-bearing potential and men must agree to use adequate contraception (hormonal, barrier method of birth control, or abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document * Toxicities from prior therapies must have resolved to baseline, or be =\< grade 2 and stable for at least one month * Patient must be able to swallow pills * Patients with central nervous system (CNS) metastases must be stable after therapy for \> 3 months and off steroid treatment prior to study enrollment Exclusion Criteria: * Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to baseline (or are not at stable grade =\< 2) from adverse events due to agents administered more than 3 weeks earlier; patients who have received immunotherapy or radioimmunotherapy within 3 months, unless disease has progressed since treatment; patients who have been administered ABT-888 as part of a single or limited dosing study, such as a phase 0 study, will not be excluded from participating in this study solely because of receiving prior ABT-888 * Patients may not be receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, bendamustine or mannitol; patients enrolling in the cohort expansion or phase 2 portions of the study who have been intolerant of repeated doses of rituximab in the past will be excluded (patients who have had infusion reactions to their initial dose of rituximab will not be excluded) * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888 * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible if their HIV is under adequate control with an antiretroviral regimen that has been stable for \>= 4 weeks, as long as the CD4 count is \> 300; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated; patients on zidovudine or stavudine would not be eligible * Patients with active seizure or a history of seizure are not eligible * Patients with uncontrolled CNS metastasis are not eligible * Patients with unrelated prior malignancies must have undergone potentially curative therapy for their prior malignancy, have no evidence of that disease for three years, or be deemed at low risk for recurrence of their prior malignancy by her/his treating physician; patients with dermal squamous cell carcinoma, basal cell carcinoma or melanoma in situ that has been completely excised will be eligible following excision
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive veliparib PO BID on days 1-7 and bendamustine hydrochloride IV over 30-60 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Once the maximum-tolerated dose is determined, a cohort of patients receives veliparib and bendamustine hydrochloride as above and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
intervention Names
Drug: Bendamustine Hydrochloride
Other: Pharmacological Study
Biological: Rituximab
Drug: Veliparib
label
Treatment (veliparib, bendamustine hydrochloride, rituximab)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (veliparib, bendamustine hydrochloride, rituximab)
description
Given IV
name
Bendamustine Hydrochloride
other Names
Bendamustin Hydrochloride
Cytostasan Hydrochloride
Levact
Ribomustin
SyB L-0501
Treanda
type
DRUG
arm Group Labels
Treatment (veliparib, bendamustine hydrochloride, rituximab)
description
Correlative studies
name
Pharmacological Study
type
OTHER
arm Group Labels
Treatment (veliparib, bendamustine hydrochloride, rituximab)
description
Given IV
name
Rituximab
other Names
BI 695500
C2B8 Monoclonal Antibody
Chimeric Anti-CD20 Antibody
IDEC-102
IDEC-C2B8
IDEC-C2B8 Monoclonal Antibody
MabThera
Monoclonal Antibody IDEC-C2B8
PF-05280586
Rituxan
Rituximab Biosimilar BI 695500
Rituximab Biosimilar PF-05280586
type
BIOLOGICAL
arm Group Labels
Treatment (veliparib, bendamustine hydrochloride, rituximab)
description
Given PO
name
Veliparib
other Names
ABT-888
PARP-1 inhibitor ABT-888
type
DRUG

Study design

intervention Model

SEQUENTIAL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 43
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Maximum Tolerated Dose (MTD) reflects the highest dose of Veliparib when combined with Bendamustine Hydrochloride that did not cause a DLT. The maximum tolerated dose (MTD) was defined as the highest dose level at which 33% of patients experienced DLT.
measure
Maximum Tolerated Dose of Veliparib When Combined With Bendamustine Hydrochloride
time Frame
28 days
description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.
measure
Response Rate
time Frame
2 years
description
Adverse events assessed by NCI CTCAE version 4.0 (Phase Ib) See adverse events section.
measure
Number of Participants With Adverse Events
time Frame
2 years

secondary Outcomes

description
Summary statistics will be used for CR. Responses will be evaluated by the International Uniform Response Criteria for Multiple Myeloma.
measure
Complete Response (CR) to Study Treatment (Phase IIa)
time Frame
2 years
measure
Duration of Remission (Phase IIa)
time Frame
From the first documented response to the first documented progression or death, assessed up to 30 days post-treatment
description
Kaplan-Meier estimates will be calculated and log-rank tests will be employed when certain comparisons are needed.
measure
Overall Survival (Phase IIa)
time Frame
Up to 30 days post-treatment
description
Area Under the Curve from time zero to 12 hours following Veliparib administration
measure
Pharmacokinetic Parameters of Veliparib (Phase Ib)
time Frame
From time zero to 12 hours on day 2 of course 1
description
Kaplan-Meier estimates will be calculated and log-rank tests will be employed when certain comparisons are needed. Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.
measure
Progression-free Survival Using RECIST Version 1.1 (Phase IIa)
time Frame
2 years
measure
Participants With Dose Limiting Toxicities
time Frame
28 days

Full study description

brief Summary: This phase I/II trial studies the side effects and the best dose of veliparib when given together with bendamustine hydrochloride and rituximab and to see how well they work in treating patients with lymphoma, multiple myeloma, or solid tumors that have come back or have not responded to treatment. Veliparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Giving veliparib together with bendamustine hydrochloride and rituximab may kill more cancer cells.
detailed Description: PRIMARY OBJECTIVES: I. To determine the maximum-tolerated dose (MTD) of ABT-888 (veliparib) in combination with bendamustine (bendamustine hydrochloride) in patients with solid tumors, lymphoma, or multiple myeloma. (Phase Ib) II. To establish the safety of ABT-888 in combination with bendamustine and rituximab in an expansion cohort of patients with non-Hodgkin lymphoma (NHL). (Phase Ib) III. To assess the toxicity profile of this regimen in the above patients. (Phase Ib) IV. To determine the complete response (CR) rate in patients with indolent NHL or mantle cell lymphoma (MCL) treated with ABT-888 + bendamustine + rituximab. (Phase IIa) SECONDARY OBJECTIVES: I. To assess response rates and survival parameters of patients treated with ABT-888 + bendamustine +/- rituximab. (Phase Ib) II. To assess pharmacokinetic parameters of ABT-888 in this regimen. (Phase Ib) III. To assess progression-free survival, overall survival, and duration of remission of patients with indolent NHL and MCL treated with ABT-888 + bendamustine + rituximab. (Phase IIa) OUTLINE: This is a phase I, dose-escalation study of veliparib followed by a phase II study. Patients receive veliparib orally (PO) twice daily (BID) on days 1-7 and bendamustine hydrochloride intravenously (IV) over 30-60 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Once the maximum-tolerated dose is determined, a cohort of patients receives veliparib and bendamustine hydrochloride as above and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days.

Source references

references

citation
Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.
pmid
28314788
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-5f9e4c8445ebec8842d4
requested nct id
NCT01326702
primary nct id
NCT01326702
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hairy+Cell+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
payload sha256
126b544f95f780ad63d10b1b95f8c889231a55899adbcfe7cc8f75cf5c0f2cdc
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-5f9e4c8445ebec8842d4
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01326702
occurrences
context exact
NCT01326702
end
11
exact text
NCT01326702
start
0
offset unit
unicode_code_points
query cond
Hairy Cell Leukemia
query disease state id
ds-hairy-cell-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hairy-cell-leukemia-000.json
source file sha256
8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
source json pointer
/studies/49/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
31be8725c145d2ac1d201a776c3043c0d65847e424c8f1fdbd098388391debbc
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hairy+Cell+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-63f648f288b0112e01ab
requested nct id
NCT01326702
primary nct id
NCT01326702
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+Undifferentiated+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
payload sha256
619a50ff2b08b1671b0690c29a2095a3cf5a4b62d47793b6591e791392a2adb6
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-63f648f288b0112e01ab
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01326702
occurrences
context exact
NCT01326702
end
11
exact text
NCT01326702
start
0
offset unit
unicode_code_points
query cond
Acute Undifferentiated Leukemia
query disease state id
ds-acute-undifferentiated-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-acute-undifferentiated-leukemia-000.json
source file sha256
a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
source json pointer
/studies/56/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
31be8725c145d2ac1d201a776c3043c0d65847e424c8f1fdbd098388391debbc
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+Undifferentiated+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-670cebea6c3738e17e03
requested nct id
NCT01326702
primary nct id
NCT01326702
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true&pageToken=ZVt07cGHkvI2wRk2CJf6_LLtzoHfMpVrd7KrgP4ZmziVu_Q-IQ
source record id
Source null
source file sha256
f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
payload sha256
a402dd782d2017b2cd9cba910e28ad844b122dd7b40edc5b06fb1204a3e7483d
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-670cebea6c3738e17e03
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01326702
occurrences
context exact
NCT01326702
end
11
exact text
NCT01326702
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-001.json
source file sha256
f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
source json pointer
/studies/0/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
31be8725c145d2ac1d201a776c3043c0d65847e424c8f1fdbd098388391debbc
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true&pageToken=ZVt07cGHkvI2wRk2CJf6_LLtzoHfMpVrd7KrgP4ZmziVu_Q-IQ
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-7f0cd926605689672637
requested nct id
NCT01326702
primary nct id
NCT01326702
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Testicular+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
payload sha256
efcdca96069bd17209bda3430737d3c7cfe90defdf1ba946c6c3727163b3ee98
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-7f0cd926605689672637
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01326702
occurrences
context exact
NCT01326702
end
11
exact text
NCT01326702
start
0
offset unit
unicode_code_points
query cond
Testicular Cancer
query disease state id
ds-testicular-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-testicular-cancer-000.json
source file sha256
9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
source json pointer
/studies/57/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
31be8725c145d2ac1d201a776c3043c0d65847e424c8f1fdbd098388391debbc
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Testicular+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-bf68f09c53c3c18f168b
requested nct id
NCT01326702
primary nct id
NCT01326702
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Small+Intestine+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
payload sha256
411d59630d786d0d1c2a149ccbc04c599d471aa4f3a66ad55282587a6fac6d4e
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-bf68f09c53c3c18f168b
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01326702
occurrences
context exact
NCT01326702
end
11
exact text
NCT01326702
start
0
offset unit
unicode_code_points
query cond
Small Intestine Cancer
query disease state id
ds-small-intestine-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
source file sha256
69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
source json pointer
/studies/126/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
31be8725c145d2ac1d201a776c3043c0d65847e424c8f1fdbd098388391debbc
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Small+Intestine+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice